Abstract
This research aims to test a new drug candidate based on a traditional medicinal herb, F1, an herbal extract obtained fromAstragalus membranaceus and its main ingredient, 1-monoli-nolein that may have fewer side effects and less uterine hypertrophy.In vitro experiments, human osteoblast-like cell lines, MG-63 and Saos-2, were analyzed by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and an alkaline phosphatase (ALP) assays. Mouse osteoclasts were induced through a calcium-deficient diet and inhibition effects were measured.In vivo experiments were done using ovariectomized (OVX) rats for 9 weeks. At necropsy, uterus weights were measured, trabecular bone area (TBA) of tibia and lumbar vertebra were measured bone histomorphology. In results, cell proliferation and ALP activity in Saos-2 by ether F1 or 1-monolinolein did not increased significantly compared to the control. The F1 inhibited osteoclast development (IC25= 3.37×10−5 mg/mL) less than 17²-estradiol. The OVX rats administered F1 (2 mg/kg/day and 10 mg/kg/day) showed an increase in TBA of the tibia significantly (136.3±4.2% and 138.5±10.3% of control). In conclusions, the herbal extract, F1 inhibited tibia and lumbar bone loss and did not cause uterine hypertrophy. However, 1-monolinolein, the main ingredient of the herbal extract, did not inhibit bone loss.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Agnusdei, D., Zucchei, R, Bigazzi, S., Cepellaro, C, Nardi, P., Montignani, M., and Gennari, C, Metabolic and clinical effects of ipriflavone in etablished post-menopausal osteoporosis.Drugs Exptl. Clin. Res., 15, 97–104 (1989).
Androanarivo, A. G., Robinson, J. A., Mann, K. G., and Tracy, R. R., Growth on type I collagen promotes expression of the osteoblastic phenotype in human osteosarcoma MG-63 cells.J. Cell Physiol., 153, 256–265 (1992).
Bergkvist, L, Admi, H. O., Persson, I., Hoover, R., and Schairer, C, The risk of breast cancer after estrogen and estrogenprogestin replacement.N. Engl. J. Med., 321, 293–297 (1989).
Bryant, H. U. and Dere, W. H., Selective estrogen receptor modultors: an alternative to hormone replacement therapy.Proc. Soc. Exp. Bio. Med., 217, 45–52 (1998).
Carmichael, J., DeGraff, W. G., Gazdar, A. F., Minna, J. D., and Mitchell, J. B., Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity.Cancer Res., 47, 936–942 (1987).
Ederveen, A. G. H., Spanjers, C. P. M., Quaijtaal, J. H. M., and Kloosterboer, H. J., Effect of 16 Months of Treatment with Tibolone on Bone Mass, Turnover, and Biomechanical Quality in Mature Ovariectomized Rats.J. Bone Miner. Res., 16, 1674–1681 (2001).
Gillespy, T., 3rd and Gillespy, M. P., Osteoporosis.Radiol. Clin. North America, 29, 77–84 (1991).
Kassem, M., Mosekilde, L., and Eriksen, E. F., 1,25-Dihydroxy-vitamin D3 potentiates fluoride-stimulated collagen type I production in cultures of human bone marrow stromal osteoblast-like cells.J. Bone Miner. Res., 8, 1453–1458 (1993).
Kassem, M., Mosekilde, L, and Eriksen, E. F., Effects of fluoride on human bone cellsin vitro: differences in responsiveness between stromal osteoblast precursors and mature osteoblasts.Eur. J. Endocrinol., 130, 381–386 (1994).
Kim, C., Kim, J. S., Kim, Y. T., and Song, K. Y., Effects of herbal medicine on tibia bone changes in ovariectomized rats and SAM P6 mice.Yakhak Hoeji, 42, 220–228 (1998).
Kim, C., Kim, J. S., Kim, Y. T., and Song, K. Y.,Korean Patent No. 0284657 (2000).
Kim, C., Ha, H., and Song, K. Y., A therapeutic agent of osteoporosis comprising an active ingredient of quercetin derivatives. WO patent # PCT/KR01/00368 (2001. 3. 9.).
Kim, C., Ha, H., Kim, J. S., Kim, Y. T., Kwon, S. C., and Park, S. W., Induction of growth hormone by the roots ofAstragalus membranaceus in pituitary cell culture.Arch. Pharm. Res., 26, 34–39 (2003).
Kobayashi, T., Sekine, S., Maekawa, Y, Suzuki, H., Shimoda, Z., and Ono, I., Roodsuffs and pharmaceuticals. European Patent # 0104043 (1983. 09. 14).
Koh, E. T., Torabinejad, M. P., Ford, T. R., Brady, K., and McDonald, F., Mineral trioxide aggregate stimulates a biological response in human.J. Biomed. Mater. Res., 37, 432–439 (1997).
Lark, M. W., Stroup, G. B., Dodds, R. A., Kapadia, R., Hoffman, S. J., Hwang, S. M., James, I. E., Lechowska, B, Liang, X., Rieman, D. J., Salyers, K. L., Ward, K., Smith, B. R., Miller, W. H., Huffman, W. F., and Gowen, M., Antagonism of the Osteoclast Vitronectin Receptor with an Orally Active Nonpeptide Inhibitor Prevents Cancellous Bone Loss in the Ovariectomized Rat.J. Bone Miner. Res., 16, 319–327 (2001).
Nordin, B. E., Heybum, P. J., and Peacock, M., Osteoporosis and osteomalacia.Clin. Metab., 9, 177–205 (1980).
Parfitt, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., Meunier, P. J., Ott, S. M., and Recker, R. R., Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee.J. Bone Miner. Res., 2, 595–610 (1987).
Ragab, A. A., Lanvish, S. A., Banks, M. A., Goldgerg, V. M., and Greenfiled, E. M., Osteoclast differentiation requires ascorbic acid.J. Bone Miner. Res., 13, 970–977 (1998).
Rosner, B.,Fundamentals of biostatistics. PWS-Kent Co., Boston, MA, USA, (1990).
Sabokbar, A., Millett, P. J., Myer, B., and Rushton, N., A rapid, quantitative assay for measuring alkaline phosphatase activity in osteoblastic cellsin vitro.Bone Miner., 27, 57–67 (1994).
Shin, G. K.,Shins Herbalogy. Sumoon-sa, Seoul, Korea, (1988).
Shioi, A., Ross, F. P., and Teitelbaum, S. L., Enrichment of generated murine osteoclasts.Calcif. Tissue Int., 55, 387–394 (1994).
Takada, Y., Kusuda, M., Hiura, K., Sato, T., Mochizuki, H., Nagao, Y., Tomura, M., Yahiro, M., Hakeda, Y., Kawashima, H., and Kumegawa, M., A simple method to assess osteocalst-mediated bone resorption using unfractionated bone cells.Bone Miner., 17, 347–359 (1992).
Wark, J. D., Osteoporotic fractures: background and prevention strategies.Maturitas, 23, 193–207 (1996).
Whitehead, M. I. and Fraser, D., Controversies concerning the safety of estrogen replacement therapy.Am. J. Obstet. Gynecol., 156, 1313–1322 (1987).
Yang, Y. M., Hyun, W., Lim, H., Sung, M. S., Kang, S. S., Paik, W. H., Bae, K. W., Cho, H., Kim, H. J., Woo, E. R., Park, H., and Park, J. G., Antineoplastic effects of extracts from traditional medicinal plants and various plants (III).Kor. J. Pharmacogn., 27, 105–110 (1996).
Proposed standard nomenclature for new tumor necrosis factor members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President’s Committee on Nomenclature.Bone, 27, 761-764 (2000).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, C., Ha, H., Lee, JH. et al. Herbal extract prevents bone loss in ovariectomized rats. Arch Pharm Res 26, 917–924 (2003). https://doi.org/10.1007/BF02980200
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02980200